S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
What to watch for as China's major political meeting of the year gets underway
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
What to watch for as China's major political meeting of the year gets underway
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
What to watch for as China's major political meeting of the year gets underway
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
What to watch for as China's major political meeting of the year gets underway
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
NASDAQ:ZVSA

ZyVersa Therapeutics (ZVSA) Stock Price, News & Analysis

$1.04
-0.06 (-5.45%)
(As of 03/1/2024 ET)
Today's Range
$1.02
$1.18
50-Day Range
$0.55
$1.10
52-Week Range
$0.50
$96.95
Volume
1.38 million shs
Average Volume
6.30 million shs
Market Capitalization
$1.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.00

ZyVersa Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
2,207.7% Upside
$24.00 Price Target
Short Interest
Healthy
10.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.08mentions of ZyVersa Therapeutics in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($86.13) to ($5.76) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.74 out of 5 stars


ZVSA stock logo

About ZyVersa Therapeutics Stock (NASDAQ:ZVSA)

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company engages in the development of VAR 200, a cholesterol efflux mediator, which is in Phase 2a clinical trial to the treatment of multiple renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic nephropathy; and IC 100, a monoclonal antibody inflammasome ASC inhibitor that is in preclinical stage for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

ZVSA Stock Price History

ZVSA Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Why Is ZyVersa Therapeutics (ZVSA) Stock Up 37% Today?
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
See More Headlines
Receive ZVSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ZyVersa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/03/2024
Next Earnings (Estimated)
3/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ZVSA
Fax
N/A
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$24.00
High Stock Price Target
$24.00
Low Stock Price Target
$24.00
Potential Upside/Downside
+2,207.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-14,120,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$386.50 per share

Miscellaneous

Free Float
1,184,000
Market Cap
$1.29 million
Optionable
Not Optionable
Beta
0.63
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Stephen C. Glover (Age 64)
    Co-Founder, Chairman, CEO & President
    Comp: $450.5k
  • Mr. Peter Wolfe (Age 56)
    CFO & Secretary
    Comp: $275k
  • Ms. Karen A. Cashmere (Age 72)
    Chief Commercial Officer
    Comp: $300k
  • Ms. Melda Uzbil O'connell
    Senior Vice President of Corporate Development
  • Dr. Pablo A. Guzman FACC (Age 74)
    M.D., Chief Medical Officer, Senior VP of Medical Affairs & Chairman of Renal Scientific Advisory Board














ZVSA Stock Analysis - Frequently Asked Questions

Should I buy or sell ZyVersa Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZyVersa Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ZVSA shares.
View ZVSA analyst ratings
or view top-rated stocks.

What is ZyVersa Therapeutics' stock price target for 2024?

1 Wall Street research analysts have issued 1 year price objectives for ZyVersa Therapeutics' stock. Their ZVSA share price targets range from $24.00 to $24.00. On average, they expect the company's share price to reach $24.00 in the next year. This suggests a possible upside of 2,207.7% from the stock's current price.
View analysts price targets for ZVSA
or view top-rated stocks among Wall Street analysts.

How have ZVSA shares performed in 2024?

ZyVersa Therapeutics' stock was trading at $0.90 at the beginning of 2024. Since then, ZVSA stock has increased by 15.6% and is now trading at $1.04.
View the best growth stocks for 2024 here
.

When is ZyVersa Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our ZVSA earnings forecast
.

When did ZyVersa Therapeutics' stock split?

Shares of ZyVersa Therapeutics reverse split on Tuesday, December 5th 2023. The 1-35 reverse split was announced on Tuesday, December 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of ZyVersa Therapeutics?

Shares of ZVSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ZVSA) was last updated on 3/3/2024 by MarketBeat.com Staff